BCM
TCRT icon

Bayesian Capital Management’s Alaunos Therapeutics TCRT Stock Holding History

Bayesian Capital Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-96
Closed -$56K – 726
2018
Q1 		$56K Buy
+96
New +$59.8K 0.01% 544
2017
Q1 		– Sell
-90
Closed -$73K – 681
2016
Q4 		$73K Buy
+90
New +$81.1K 0.02% 570

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bayesian Capital Management's TCRT Position: Q2 2018 in Review

Bayesian Capital Management sold out of Alaunos Therapeutics (TCRT) in Q2 2018, closing a stake of 96 shares — an estimated $56K sold.

Bayesian Capital Management first reported a position in TCRT in Q4 2016 and held it in 2 quarters. The position peaked at $73K in Q4 2016. 133 funds tracked by Wall St. Rank hold TCRT as of Q2 2018.

  • Bayesian Capital Management reported no remaining Alaunos Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Bayesian Capital Management sold 96 Alaunos Therapeutics shares in Q2 2018, an estimated $56K.
  • Bayesian Capital Management first reported a position in Alaunos Therapeutics in Q4 2016 and held it in 2 quarters.
  • Bayesian Capital Management's Alaunos Therapeutics position peaked at $73K in Q4 2016.
  • 133 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2018.

Based on Bayesian Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.